Currently, the number of cases of refractory moderate-to-severe ulcerative colitis is increasing. Clinical investigations and research indicate that these cases account for over 70% of all ulcerative colitis, making them challenging to treat and manage. By integrating clinical practice experiences from both domestic and international sources, and through the continuous updating of research materials, this article provides a comprehensive overview of the treatment options for intractable moderate and severe ulcerative colitis, as well as a discussion of common clinical medications used in their management.
References
[1]
Zou, L., Fan, L. and Meng, F. (2023) The Impact of Vedolizumab Combined with Mesal on Intestinal Flora and Inflammatory Factors in Patients with Moderate-to-Severe Ulcerative Colitis. China Medical Innovation, 20, 41-45.
[2]
Wang, H., Ye, C. and Wang, X. (2020) Research Progress on the Treatment of Biics for Refractory Moderate-to-Severe Ulcerative Colitis. Journal of Tongji University (Medical Edition), 41, 136-140.
[3]
Gu, T. and Zhang, W. (2014) Advances in the Treatment of Refract and Severe Ulcerative Colitis. Chinese Journal of Health Care Medicine, 16, 402-444.
[4]
Inflammatory Bowel Disease Group of the Chinese Society of Gastroenterology (2012) Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease (Guzhou 2012). Gastroenterology, 17, 763-778.
[5]
Wu, D., Li, Y., Wang, L., et al. (2016) Analysis of Clinical Characteristics of Severe Ulcerative Colitis Combined with Opportunistic. Chinese Journal of Practical Internal Medicine, 36, 482-484.
[6]
Chen, J., Gan, S., Chen, Z., et al. (2016) Analysis of the Relationship between Cytomegalovirus Infection and Refractory Ulcerativeitis. Modern Diagnosis and Treatment, 27, 2495-2496.
[7]
Wu, D. and Qian, J. (2012) Clinical Case Discussion No. 412-Diarrhea, Fever, Dyspnea. Chinese Journal of Internal Medicine, 51, 174-176.
[8]
Hu, H., Yang, H., Wang, Z., et al. (2018) Efficacy Analysis of Thalidomide in the Treatment of 11 Cases of Refractory Adult Ulcerativeitis. Chinese Journal of Practical Internal Medicine, 38, 223-226.
[9]
Edfors, K., Ståhlberg, D. and Söderman, C. (2016) Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment Ininflammatory Bowel Disease. Therapeutic Apheresis and Dialysis, 20, 79-85. https://doi.org/10.1111/1744-9987.12336
[10]
Shehab, M., Alrashed, F., Alsayegh, A., et al. (2025) Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis. Clinical Gastroenterology and Hepatology, 23, 250-262. https://doi.org/10.1016/j.cgh.2024.07.033
[11]
Thanaraj, S., Hamlin, P.J. and Ford, A.C. (2010) Systematic Review: Granulocyte/Monocyte Adsorptive Apheresis for Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 32, 1297-1306.
